1. health and fitness

Intercellular Adhesion Molecule 1 (CD54) Market Share, Size,
Treatment, Symptoms, Pipeline Review, H1 2016: Radiant
Insights
Summary
Global Markets Direct's, 'Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) Pipeline Review, H1 2016', provides in depth analysis on Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group
Rhinovirus Receptor or CD54) targeted pipeline therapeutics.
The report provides comprehensive information on the Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group
Rhinovirus Receptor or CD54) , targeted therapeutics, complete with analysis by indications, stage of development,
mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the
descriptive pharmacological action of the therapeutics, its complete research and development history and latest
news and press releases. Additionally, the report provides an overview of key players involved in Intercellular
Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) targeted therapeutics development
and features dormant and discontinued projects.
Click For Report Details @ http://www.radiantinsights.com/research/intercellular-adhesion-molecule-1
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and
nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's
proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and industry-specific third party sources.
Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that
all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes
ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision
making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape for Intercellular Adhesion Molecule 1 (ICAM-1
or Major Group Rhinovirus Receptor or CD54)
- The report reviews Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54)
targeted therapeutics under development by companies and universities/research institutes based on information
derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till
discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description,
descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus
Receptor or CD54) targeted therapeutics and enlists all their major and minor projects
- The report assesses Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54)
targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group
Rhinovirus Receptor or CD54) targeted therapeutics
Reasons To Buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain
competitive advantage
- Identify and understand the targeted therapy areas and indications for Intercellular Adhesion Molecule 1 (ICAM-1
or Major Group Rhinovirus Receptor or CD54)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Intercellular Adhesion Molecule 1 (ICAM-1 or
Major Group Rhinovirus Receptor or CD54) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most
attractive projects to enhance and expand business potential and scope
Buy a Sample Copy of This Report @ http://www.radiantinsights.com/research/intercellular-adhesionmolecule-1/request-sample
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) Overview 6
Therapeutics Development 7
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Products under
Development by Stage of Development 7
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Products under
Development by Therapy Area 8
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Products under
Development by Indication 9
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Pipeline Products
Glance 10
Late Stage Products 10
Early Stage Products 11
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Products under
Development by Companies 12
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Products under
Development by Universities/Institutes 14
Intercellular Adhesion Molecule 1 (ICAM-1 or Major Group Rhinovirus Receptor or CD54) - Therapeutics
Assessment 16
Assessment by Monotherapy/Combination Products 16
Assessment by Mechanism of Action 17
Assessment by Route of Administration 18
Assessment by Molecule Type 20
Click For Report Details @ http://www.radiantinsights.com/research/intercellular-adhesion-molecule-1
About Us:
Radiant Insights Inc. is a platform for companies looking to meet their market research and business intelligence
requirements. We assist and facilitate organizations and individuals procure market research reports, helping them
in the decision making process. We have a comprehensive collection of reports, covering over 40 key industries
and a host of micro markets. In addition to over extensive database of reports, our experienced research
coordinators also offer a host of ancillary services such as, research partnerships/ tie-ups and customized research
solutions.
Contact Details:
Michelle Thoras
Corporate Sales Specialist, USA
Radiant Insights, Inc
28 2nd Street,
Suite 3036 San Francisco,
CA 94105 United States
Phone: 1-415-349-0054
Toll Free: 1-888-202-9519
Website: http://www.radiantinsights.com/
Email: sales@radiantinsights.com
Visit our Blog: http://chemicalsandmaterialsri.blogspot.com